

EXCLUSION CRITERIA
Necrotizing fasciitis
Immunocompromised
Sepsis
Postoperative wound infection
Animal bite
Osteomyelitis
Septic arthritis
Perianal/perirectal cellulitis/abscess
Periorbital/orbital cellulitis
Breast abscess
Pilonidal abscess
Dental abscess
Deep neck infection
Cervical lymphadenitis
Chronic or recurrent cellulitis/abscess at same site
Pressure ulcer

INCLUSION CRITERIA

All children > 59 days of age with suspected skin and soft tissue infection

History and Physical

Suspected deeper infection (at fascia or deeper)

Manage off Pathway

Note for symptoms of redness, warmth, and tenderness

History of Purulence?

See [Picture Atlas](#) to distinguish between Cellulitis vs Normal Inflammation associated with an abscess

Cellulitis (non-purulent)

Cellulitis w/potential fluctuance

Definite Abscess

Antibiotic Recommendations

Consider Ultrasound

Drainage procedure

Drainable collection?

1 Admit*
Manage on Inpatient SSTI Pathway

Discharge**
Discharge Instructions

Discharge**
Discharge Instructions

1 Admit*
Manage on Inpatient SSTI Pathway

INPATIENT ADMISSION CONSIDERATIONS

- Systemic symptoms
ill-appearing, hemodynamic instability, significant fever
concern for Sepsis
- Rapidly expanding or large lesion (>3 cm; significant cellulitis after abscess drainage)
- Age <2 months
- Concern for inadequate drainage of large abscess
- Abscess location that requires subspecialty consult
- Unable to tolerate oral antibiotics
- Significant pain
- Failed OP treatment with appropriate antibiotics, no improvement
- Follow-up concerns


* Review admissions considerations (Use clinical judgment to admit or discharge)

** Follow-up – Patient should have scheduled follow-up in 48-72 hours.

★ Consider ultrasound only in cases of indeterminate clinical assessment for abscess.

INPATIENT ADMISSION CONSIDERATIONS

- Systemic symptoms
ill-appearing, hemodynamic instability, significant fever
concern for Sepsis
- Rapidly expanding or large lesion (>3 cm; significant cellulitis after abscess drainage)
- **Age <2 months**
- Concern for inadequate drainage of large abscess
- Abscess location that requires subspecialty consult
- Unable to tolerate oral antibiotics
- Significant pain
- Failed OP treatment with appropriate antibiotics, no improvement
- Follow-up concerns



★ Consider ultrasound only in cases of indeterminate clinical assessment for abscess.

History

- Fever, other systemic symptoms
- Number and location of abscess(es)
- Duration of lesion
- Rapidity of spread
- Previous history of pustule, abscess, folliculitis
- Family history or abscess, MRSA
- Break in skin barrier
 - Abrasion
 - Insect bite
 - Dermatologic condition
- Concern for possible foreign body
- Infection due to animal bite
- Previous antibiotic use, including topical antibiotics
- Previous home remedies

Physical Exam

- Assess Vital Signs, pain
- Location, size of lesion (measure, outline, photograph)
- Induration, swelling, fluctuance, erythema, ulceration, eschar, or lymphangitic streaking
- Spontaneous drainage
- Overlying or surrounding cellulitis
- Regional adenopathy
- Rash or existing skin condition

Picture Atlas:

Abscess with surrounding inflammation




Photo courtesy of Mayo Foundation for Medical Education and Research

Cellulitis (Non-purulent)



Photo courtesy of Coreem.net/skin and soft tissue infection

Abscess with Papule w/ surrounding Inflammation



Photo courtesy of Texas <https://www.drjagoda.com/jent-medicine/ent-head-neck/neck-abscesses/>, of Public Health

Ultrasound abscess with surrounding Cellulitis



<https://www.coreem.net/core/folliculitis>

Ultrasound

- Findings consistent with cellulitis
 - Tissue edema
 - "Cobblestoning"
- Helpful in differentiating cellulitis from abscess

Addendum 1: Guideline for SSTI Antibiotic Selection and Dosing

Disposition	Medication	Dosing Regimen
Non-Purulent Cellulitis: First-Line[^]		
Sepsis/SIRS	Refer to Sepsis ED/Inpatient guideline for antimicrobial recommendations	
Inpatient	Cefazolin (IV)	33 mg/kg/dose IV q8h (max 1000 mg/dose)
Outpatient	Cephalexin (PO)	25 mg/kg/dose PO q8h (max 1000 mg/dose)
Non-Purulent Cellulitis: History of Type I reaction or SEVERE adverse reaction to Cefazolin		
Inpatient	Vancomycin (IV)	See Vancomycin Dosing Guideline
Outpatient	Clindamycin (PO)	10 mg/kg/dose PO q8h (max 450 mg/dose PO)
Purulent Cellulitis: First-Line		
Sepsis/SIRS	Refer to Sepsis ED/Inpatient guideline for antimicrobial recommendations	
Inpatient without systemic signs of infection	Clindamycin (IV)	13 mg/kg/dose IV q8h (max 600 mg/dose)
	SMX/TMP* (PO)	5 mg/kg/dose of TMP* PO q12h (max 320 mg of TMP/dose)
Outpatient	SMX/TMP* (PO)	5 mg/kg/dose of TMP* PO q12h (max 320 mg of TMP/dose)
Outpatient (If MSSA)	Cephalexin (PO)	25 mg/kg/dose PO q8h (max 1000 mg/dose)
Purulent Cellulitis: History of Type I reaction or SEVERE adverse reaction to Sulfa		
Inpatient (If MRSA susceptible to clindamycin)	Clindamycin (IV)	13 mg/kg/dose IV q8h (max 600 mg/dose)
Inpatient	Vancomycin (IV)	See Vancomycin Dosing Guideline
Outpatient	Doxycycline (PO) <i>≥8 years only</i>	2 mg/kg/dose PO q12h(max 100 mg/dose)
Outpatient (If MRSA susceptible to clindamycin)	Clindamycin (PO)	10 mg/kg/dose PO q8h (max 450 mg/dose PO)
Outpatient (If MSSA)	Cephalexin (PO)	25 mg/kg/dose PO q8h (max 1000 mg/dose)

*SMX/TMP: sulfamethoxazole/trimethoprim

[^] SMX/TMP recommended if personal or family history of MRSA; Avoid using SMX/TMP if abscess has not been drained

EBOC Project Owner: Jennifer Hughes, MD, FAAP

Approved by the Pediatric Evidence-Based Outcomes Center Team

Revision History

Original Date Approved: March 2021

Next Review Date: March 2023

SSTI EBOC Team:

Kathryn Merkel, PharmD
Leah Jorgensen, DO
Jason Gillon, MD
Peter Gilbreath, MD
Nalinda Charnsangavej, MD
Claire Hebner, MD
Ayesha Irani, DO
Julia Sapozhnikov, PharmD
Eric Grethel, MD
Marisol Fernandez, MD
Logan Rencher, DO
Nalinda Charnsangavej, MD
Julio Ortiz, MD
Ronda Machen, PharmD
Coburn Allen, MD
Carmen Garudo, PM

EBOC Committee:

Lynn Thoreson, DO
Sarmistha Hauger, MD
Terry Stanley, DNP
Sujit Iyer, MD
Tory Meyer, MD
Nilda Garcia, MD
Meena Iyer, MD
Amanda Puro, MD